How is IGF-1 LR3 different from regular IGF-1?

IGF-1 LR3 has a modified amino acid at position 3 and a 13-amino acid extension that dramatically reduce binding protein affinity. This means far more of the compound stays active in the body and for much longer (20+ hours vs ~20 minutes for native IGF-1). The result is a more potent growth signal, but also potentially amplified risks.

Does IGF-1 LR3 build muscle?

Animal studies demonstrate increased protein accretion and muscle growth. The mechanism through IGF-1R activation and mTOR-mediated protein synthesis is well-characterized. However, no controlled human trials have measured muscle growth outcomes with IGF-1 LR3. Community use reports are extensive but uncontrolled.

Is IGF-1 LR3 FDA-approved?

No. IGF-1 LR3 is not FDA-approved and has never undergone regulatory evaluation. Native IGF-1 (mecasermin, brand name Increlex) is FDA-approved for severe primary IGF-1 deficiency in children, but that is a different compound.

Can IGF-1 LR3 cause cancer?

This is a theoretical concern, not a confirmed risk. IGF-1R signaling is implicated in multiple cancer pathways, and supraphysiological IGF-1 activity could theoretically promote the growth of pre-existing malignancies. No controlled human studies have quantified this risk for IGF-1 LR3 specifically. Discuss with a physician before considering use.

What does the research show about: Francis et al. (1992): Developed and characterized the LR3 IGF-1 analog, demonst?

Francis et al. (1992): Developed and characterized the LR3 IGF-1 analog, demonstrating the dramatic reduction in IGFBP binding that defines the compound.. Foundational work establishing the pharmacological basis for IGF-1 LR3

What does the research show about: Tomas et al. (1998): Demonstrated increased protein accretion and muscle growth ?

Tomas et al. (1998): Demonstrated increased protein accretion and muscle growth in animal models, establishing the biological activity of the LR3 modification.. Key animal study supporting the muscle growth mechanism

What does the research show about: IGFBP affinity reduction to less than 1% of native IGF-1 results in dramatically?

IGFBP affinity reduction to less than 1% of native IGF-1 results in dramatically higher free IGF-1 activity and extended half-life (20+ hours vs ~20 minutes).. The core pharmacological advantage that drives both research use and community interest

reviewed april 2026|next review october 2026|88 physicians psi has verified|43 published studies

IGF-1 LR3

Q: Is IGF-1 LR3 safe?

There is no established safety profile from controlled human clinical trials. The primary theoretical concern is tumor promotion from supraphysiological IGF-1R signaling. Hypoglycemia is a documented risk of IGF-1 analogs. Without controlled human data, the safety profile is substantially uncharacterized.

IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is an 83-amino-acid recombinant analog of insulin-like growth factor-1 with dramatically reduced binding protein affinity (less than 1% of native IGF-1), extending biological half-life from approximately 20 minutes to over 20 hours.

Evidence landscape: 43 published studies

43 published items. 1 human study and 41 animal studies.

1 Human
41 Animal
1 Reviews

Not FDA-approved. Not on any FDA list that regulates specialty pharmacy preparation of medicines. Classified as a research compound. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 is a distinct analog that has never undergone regulatory evaluation.

43 published studies including 1 human study and 41 animal studies. Controlled human clinical trials specifically with IGF-1 LR3 are virtually absent despite wide community use. Extensive cell culture and animal model data.

The Glu3Arg substitution and 13-amino-acid N-terminal extension reduce IGFBP binding to less than 1% of native IGF-1. This dramatically increases free IGF-1 activity, activating PI3K/Akt/mTOR and MAPK/ERK pathways for cell proliferation and protein synthesis.

PSI Assessment

The evidence profile for IGF-1 LR3 is defined by a striking gap: it is one of the most widely used growth factors in both research laboratories and performance communities, yet controlled human clinical trials are virtually absent. The pharmacological design is sound - reducing binding protein affinity to less than 1% of native IGF-1 extends the biological half-life from approximately 20 minutes to over 20 hours. Animal data demonstrates increased protein accretion and muscle growth. But the gap between laboratory use and clinical evidence is among the widest for any compound with this level of community interest. Supraphysiological IGF-1 receptor signaling carries theoretical risks of promoting tumor growth that remain unquantified without human safety data.

Binding protein affinity reduced to less than 1% of native IGF-1. Biological half-life extended from 20 minutes to over 20 hours. Controlled human clinical trials are virtually absent.

The mechanism is well-characterized at the molecular level. The Glu3Arg substitution at position 3 disrupts the primary IGFBP binding site, reducing affinity for IGFBP-1 through IGFBP-6 by approximately 100-fold. The 13-amino-acid N-terminal extension further reduces binding. Native IGF-1 is approximately 99% bound to IGFBPs in circulation; IGF-1 LR3 remains largely in its free, bioactive form. It binds the IGF-1 receptor with similar affinity to native IGF-1, activating PI3K/Akt/mTOR signaling (protein synthesis, anti-apoptotic) and MAPK/ERK signaling (cell proliferation, differentiation). Native IGF-1 as mecasermin (Increlex) is FDA-approved for severe IGF-1 deficiency, providing regulatory validation that the IGF-1 pathway produces clinical effects in humans.

What the evidence supports

IGF-1 LR3 achieves dramatically higher free IGF-1 activity through reduced IGFBP binding (less than 1% of native affinity) and extended half-life. The Glu3Arg substitution and N-terminal extension are well-characterized biochemically. Animal data demonstrates increased protein accretion and muscle growth. Cell culture applications are standard across the research field. Native IGF-1 (mecasermin/Increlex) is FDA-approved for severe IGF-1 deficiency, providing regulatory validation of the IGF-1 pathway.

What is not yet established

Controlled human clinical trials for IGF-1 LR3 are virtually absent despite wide community use. Whether the dramatically increased free IGF-1 activity translates to proportionally greater clinical effects versus native IGF-1. Quantification of the tumor promotion risk from sustained supraphysiological IGF-1R signaling. Long-term safety profile.

Research Evidence

The findings below cover what the laboratory and animal evidence has established and where the gap to human clinical evidence is most significant.

Evidence by condition

Evidence dimensions across IGF-1 LR3 research areas. Muscle growth has the most consistent animal data. Tissue repair and metabolic effects have mechanism support but limited direct evidence. Neuroprotection is at the earliest stage.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Muscle Growth
Tissue Repair
Metabolic Effects
Neuroprotection

The Glu3Arg substitution and N-terminal extension reduce IGFBP binding to less than 1% of native IGF-1, extending biological half-life from approximately 20 minutes to over 20 hours. This dramatically increases free IGF-1 activity available to activate the IGF-1 receptor.

The pharmacological design is validated at the biochemical level. Whether the increased potency translates to proportionally greater clinical effects in humans is untested.

Animal studies demonstrate increased protein accretion and muscle growth with IGF-1 LR3 administration. The enhanced bioavailability relative to native IGF-1 is confirmed across multiple animal models.

The animal growth data supports the mechanism. No controlled human trial has measured muscle growth outcomes with IGF-1 LR3 specifically.

Supraphysiological IGF-1R signaling is implicated in multiple cancer pathways. The combination of high potency, extended half-life, and absent human safety data means the tumor promotion risk is theoretical but unquantified.

This is the primary safety concern. Native IGF-1 (mecasermin) carries a black box warning regarding tumor risk at supraphysiological levels. IGF-1 LR3 achieves even higher free IGF-1 activity with no safety monitoring framework.

1 Human|41 Animal|1 Reviews

View all 43 indexed studies

How IGF-1 LR3 Works

IGF-1 LR3 is an 83-amino-acid engineered version of insulin-like growth factor-1, which means it is a modified form of one of the body's natural growth signals. It has been specifically designed so that the proteins in blood that normally capture and inactivate IGF-1 cannot grab onto it.

Your body naturally produces IGF-1 (insulin-like growth factor 1), a hormone that signals cells to grow and repair. Normally, binding proteins in your blood grab onto IGF-1 and limit how much of it is actually active at any given time. IGF-1 LR3 has been engineered to slip past those binding proteins, meaning far more of it stays active for far longer. The result is a much stronger growth signal to muscle and other tissues.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

IGF-1 LR3 is a recombinant analog of human IGF-1 with a 13-amino-acid N-terminal extension peptide and a substitution of arginine for glutamic acid at position 3 (Glu3Arg). These modifications reduce IGFBP affinity to less than 1% of native IGF-1, dramatically increasing circulating free IGF-1 activity and extending biological half-life from approximately 20 minutes to over 20 hours. It binds the IGF-1 receptor (IGF-1R) with similar affinity to native IGF-1, activating PI3K/Akt (protein synthesis via mTOR, anti-apoptotic via FOXO phosphorylation) and MAPK/ERK (cell proliferation, differentiation) signaling cascades.

What is IGF-1 LR3 being studied for?

Researchers are studying IGF-1 LR3 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for IGF-1 LR3 overall. This means a compound can have human studies for one condition but only animal data for another.

Muscle Growth

·Human Trials

Animal studies demonstrate increased protein accretion and muscle growth. The IGF-1R activation mechanism is well-characterized. Controlled human trials specifically with IGF-1 LR3 are absent.

Limitations: No controlled human trials with IGF-1 LR3 specifically. Community use reports are extensive but uncontrolled.

Tissue Repair

·Animal Studies

IGF-1 signaling plays a well-documented role in tissue repair. IGF-1 LR3's enhanced bioavailability theoretically amplifies this effect.

Limitations: No controlled human tissue repair trials with IGF-1 LR3. Evidence is extrapolated from native IGF-1 biology.

Metabolic Effects

·Animal Studies

IGF-1 has documented effects on glucose metabolism and insulin sensitivity. IGF-1 LR3's enhanced activity may amplify metabolic effects but also raises concerns about hypoglycemia.

Limitations: No controlled metabolic studies with IGF-1 LR3. Hypoglycemia risk is theoretical but plausible based on IGF-1 pharmacology.

Neuroprotection

·Preclinical

IGF-1 has documented neuroprotective properties in animal studies (animal models). Whether IGF-1 LR3 crosses the blood-brain barrier effectively is unknown.

Limitations: Extremely limited data. No human neuroprotection studies with any IGF-1 analog.

Safety and Regulatory Status

FDA Status: Not FDA-approved. Not on any FDA list that regulates specialty pharmacy preparation of medicines. Classified as a research compound. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 is a distinct analog.

Availability: Available as a research compound from peptide suppliers. Not available through standard pharmacies or specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.

Class context: Supraphysiological IGF-1R signaling is implicated in multiple cancer pathways. Hypoglycemia is a documented risk of IGF-1 analogs. The combination of high potency, extended half-life, and absent human safety data means the risk profile is substantially uncharacterized.

IGF-1 LR3 has no established human safety profile from controlled clinical trials. The primary theoretical concern is tumor promotion from supraphysiological IGF-1R signaling. Hypoglycemia is a documented risk of IGF-1 analogs generally. Native IGF-1 (mecasermin) carries a black box warning regarding tumor risk.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a IGF-1 LR3 discussion.

Comparison and Related Research

IGF-1 LR3 is most often compared with other growth factors in the IGF-1 pathway. The comparisons below outline how each differs.

Head-to-head comparisons

Full research comparisons covering IGF-1 LR3 and another peptide side by side.

IGF-1 LR3 vs MK-677

Research comparison of MK-677 and IGF-1 LR3, an oral GH secretagogue versus a direct IGF-1 receptor analog. Mechanisms, evidence levels, administration contexts, and limitations analyzed.

View full comparison

IGF-1 LR3 vs HGH (Somatropin)

HGH tells your liver to make IGF-1. IGF-1 LR3 is the product itself. Evidence-graded comparison of direct vs indirect growth factor approaches.

View full comparison

Related compounds

Mechano Growth Factor PEG-MGF Follistatin ACE-031 IGF-1 DES

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Characterized the biological properties of recombinant IGF-I analogs including Long-R3-IGF-I (LR3-IGF-I). The study demonstrated that modifications reducing binding protein affinity while preserving receptor binding resulted in dramatically enhanced biological potency. This work established the foundational understanding of why LR3-IGF-I is more potent than native IGF-I in cell culture systems.Francis GL et al., 1992 in J Mol Endocrinol. View on PubMed
2.Compared the anabolic effects of native IGF-I and the Long-R3 variant in rat models. LR3-IGF-I demonstrated substantially greater protein accretion and tissue growth compared to equimolar doses of native IGF-I, confirming that reduced binding protein sequestration translates to enhanced anabolic activity in living systems.Tomas FM et al., 1993 in J Endocrinol. View on PubMed
3.A review of IGF-I analogs with reduced binding protein affinity, covering the biochemistry and biological activity of modified IGF-I forms. This paper placed the LR3 and Des(1-3) variants in context, explaining how structural modifications that reduce IGFBP binding lead to increased free IGF-I availability and enhanced biological activity.Ballard FJ et al., 1996 in Int J Biochem Cell Biol. View on PubMed
4.A comprehensive review of IGF-1 and its splice variants in skeletal muscle biology, covering the roles of different IGF-1 isoforms in muscle development, repair, and hypertrophy. This paper provides important context for understanding how modified IGF-1 peptides like LR3-IGF-I relate to the broader IGF-1 signaling system in muscle tissue.Philippou A et al., 2007 in In Vivo. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.